- Home
- TLSI vs DLNG Comparison
TLSI vs DLNG Comparison
Compare TLSI & DLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- DLNG
- Stock Information
- Founded
- TLSI 2010
- DLNG 2013
- Country
- TLSI United States
- DLNG Greece
- Employees
- TLSI N/A
- DLNG N/A
- Industry
- TLSI Medical Specialities
- DLNG Marine Transportation
- Sector
- TLSI Health Care
- DLNG Consumer Discretionary
- Exchange
- TLSI Nasdaq
- DLNG Nasdaq
- Market Cap
- TLSI 150.0M
- DLNG 129.0M
- IPO Year
- TLSI N/A
- DLNG 2013
- Fundamental
- Price
- TLSI $4.80
- DLNG $3.75
- Analyst Decision
- TLSI Strong Buy
- DLNG
- Analyst Count
- TLSI 5
- DLNG 0
- Target Price
- TLSI $10.90
- DLNG N/A
- AVG Volume (30 Days)
- TLSI 95.6K
- DLNG 38.5K
- Earning Date
- TLSI 11-13-2025
- DLNG 09-08-2025
- Dividend Yield
- TLSI N/A
- DLNG 5.23%
- EPS Growth
- TLSI N/A
- DLNG 98.62
- EPS
- TLSI N/A
- DLNG 1.19
- Revenue
- TLSI $35,990,000.00
- DLNG $158,453,000.00
- Revenue This Year
- TLSI $56.79
- DLNG N/A
- Revenue Next Year
- TLSI $54.15
- DLNG $0.37
- P/E Ratio
- TLSI N/A
- DLNG $3.18
- Revenue Growth
- TLSI 45.50
- DLNG N/A
- 52 Week Low
- TLSI $3.42
- DLNG $3.18
- 52 Week High
- TLSI $5.88
- DLNG $5.65
- Technical
- Relative Strength Index (RSI)
- TLSI 51.02
- DLNG 53.94
- Support Level
- TLSI $4.41
- DLNG $3.79
- Resistance Level
- TLSI $4.93
- DLNG $3.90
- Average True Range (ATR)
- TLSI 0.28
- DLNG 0.09
- MACD
- TLSI -0.05
- DLNG 0.00
- Stochastic Oscillator
- TLSI 42.25
- DLNG 57.14
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About DLNG Dynagas LNG Partners LP Common Units
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.